|
1
|
Surawicz TS, Davis F, Freels S, Laws ER Jr
and Menck HR: Brain tumor survival: results from the National
Cancer Data Base. J Neurooncol. 40:151–160. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bondy ML, Scheurer ME, Malmer B, et al:
Brain tumor epidemiology: consensus from the Brain Tumor
Epidemiology Consortium. Cancer. 113:1953–1968. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chargari C, Moncharmont C, Lévy A, et al:
Cancer stem cells, cornerstone of radioresistance and perspectives
for radiosensitization: glioblastoma as an example. Bull Cancer.
99:1153–1160. 2012.(In French).
|
|
4
|
Schepeler T: Emerging roles of microRNAs
in the Wnt signaling network. Crit Rev Oncog. 18:357–371. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nikaki A, Piperi C and Papavassiliou AG:
Role of microRNAs in gliomagenesis: targeting miRNAs in
glioblastoma multiforme therapy. Expert Opin Investig Drugs.
21:1475–1488. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Profumo V and Gandellini P: MicroRNAs:
cobblestones on the road to cancer metastasis. Crit Rev Oncog.
18:341–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar
|
|
9
|
Noguchi S, Mori T, Otsuka Y, et al:
Anti-oncogenic microRNA-203 induces senescence by targeting E2F3
protein in human melanoma cells. J Biol Chem. 287:11769–11777.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schetter AJ, Leung SY, Sohn JJ, et al:
MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boll K, Reiche K, Kasack K, et al:
MiR-130a, miR-203 and miR-205 jointly repress key oncogenic
pathways and are downregulated in prostate carcinoma. Oncogene.
32:277–285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan Y, Zeng ZY, Liu XH, et al:
MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63
expression in human esophageal squamous cell carcinoma. BMC Cancer.
11:572011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He J, Deng Y, Yang G and Xie W:
MicroRNA-203 down-regulation is associated with unfavorable
prognosis in human glioma. J Surg Oncol. 108:121–125. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bian K, Fan J, Zhang X, et al:
MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal
carcinoma cells by directly targeting survivin. FEBS Lett.
586:804–809. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang C, Zheng X, Shen C and Shi Y:
MicroRNA-203 suppresses cell proliferation and migration by
targeting BIRC5 and LASP1 in human triple-negative breast cancer
cells. J Exp Clin Cancer Res. 31:582012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei W, Wanjun L, Hui S, Dongyue C, Xinjun
Y and Jisheng Z: miR-203 inhibits proliferation of HCC cells by
targeting survivin. Cell Biochem Funct. 31:82–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rani SB, Rathod SS, Karthik S, Kaur N,
Muzumdar D and Shiras AS: MiR-145 functions as a tumor-suppressive
RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro
Oncol. 15:1302–1316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He Z, Cen D, Luo X, et al: Downregulation
of miR-383 promotes glioma cell invasion by targeting insulin-like
growth factor 1 receptor. Med Oncol. 30:5572013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao H, Zhao H and Xiang W: Expression
level of human miR-34a correlates with glioma grade and prognosis.
J Neurooncol. 113:221–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei T, Xu N, Meisgen F, Ståhle M, Sonkoly
E and Pivarcsi A: Interleukin-8 is regulated by miR-203 at the
posttranscriptional level in primary human keratinocytes. Eur J
Dermatol. Apr 19–2013.(Epub ahead of print).
|
|
22
|
Abella V, Valladares M, Rodriguez T, et
al: miR-203 regulates cell proliferation through its influence on
Hakai expression. PLoS One. 7:e525682012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeshita N, Mori M, Kano M, et al:
miR-203 inhibits the migration and invasion of esophageal squamous
cell carcinoma by regulating LASP1. Int J Oncol. 41:1653–1661.
2012.PubMed/NCBI
|
|
24
|
Szumiło M and Rahden-Staroń I:
Phospholipase D in mammalian cells: structure, properties,
physiological and pathological role. Postepy Hig Med Dosw (Online).
60:421–430. 2006.(In Polish).
|
|
25
|
Gomez-Cambronero J: Biochemical and
cellular implications of a dual lipase-GEF function of
phospholipase D2 (PLD2). J Leukoc Biol. 92:461–467. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Y, Ehara H, Akao Y, et al: Increased
activity and intranuclear expression of phospholipase D2 in human
renal cancer. Biochem Biophys Res Commun. 278:140–143. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eisen SF and Brown HA: Selective estrogen
receptor (ER) modulators differentially regulate phospholipase D
catalytic activity in ER-negative breast cancer cells. Mol
Pharmacol. 62:911–920. 2002. View Article : Google Scholar
|
|
28
|
Meacci E, Nuti F, Catarzi S, et al:
Activation of phospholipase D by bradykinin and sphingosine
1-phosphate in A549 human lung adenocarcinoma cells via different
GTP-binding proteins and protein kinase C delta signaling pathways.
Biochemistry. 42:284–292. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saito M, Iwadate M, Higashimoto M, Ono K,
Takebayashi Y and Takenoshita S: Expression of phospholipase D2 in
human colorectal carcinoma. Oncol Rep. 18:1329–1334.
2007.PubMed/NCBI
|
|
30
|
Snider AJ, Zhang Z, Xie Y and Meier KE:
Epidermal growth factor increases lysophosphatidic acid production
in human ovarian cancer cells: roles for phospholipase D2 and
receptor transactivation. Am J Physiol Cell Physiol. 298:C163–C170.
2010. View Article : Google Scholar
|
|
31
|
O’Reilly MC, Scott SA, Brown KA, et al:
Development of dual PLD1/2 and PLD2 selective inhibitors from a
common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and
Ml299 that decrease invasive migration in U87-MG glioblastoma
cells. J Med Chem. 56:2695–2699. 2013.PubMed/NCBI
|
|
32
|
Choi HJ and Han JS: Overexpression of
phospholipase D enhances Bcl-2 expression by activating STAT3
through independent activation of ERK and p38MAPK in HeLa cells.
Biochim Biophys Acta. 1823:1082–1091. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ahn BH, Park MH, Lee YH, Kwon TK and Min
do S: Up-regulation of cyclooxygenase-2 by cobalt chloride-induced
hypoxia is mediated by phospholipase D isozymes in human
astroglioma cells. Biochim Biophys Acta. 1773:1721–1731. 2007.
View Article : Google Scholar : PubMed/NCBI
|
